Nabla Bio, a Boston MA-based antibody design company, raised $11M in Seed funding.
The round was led by Khosla Ventures and Zetta Venture Partners with participation from Fifty Years and Cantos Ventures.
The company intends to use the funds to accelerate development of an AI-first protein design platform, enabling rapid end-to-end engineering of next-generation antibody therapeutics.
Nabla is developing a high-throughput technology that enables generation of a predictive “biophysical fingerprint” for 1 million antibodies in a single step. Combined with proprietary advances in protein language modeling, the platform enables the design and optimization of antibodies that clear multiple end-stage drug development criteria, maximizing the probability of clinical and commercial success. The foundational technology was developed by CEO Surge Biswas, academic Co-Founder George Church and their team at Harvard, and has advanced the field of machine learning-guided protein modeling and design. The other co-founder was Frances Anastassacos, Ph.D.